Immunotherapy, a revolutionary approach to cancer treatment, has garnered significant attention in the medical community. This technique leverages the body's immune system to combat cancerous cells, offering a promising alternative to traditional treatments. This article aims to elucidate the essential aspects of immunotherapy for physicians.
Immunotherapy, also known as biotherapy, involves stimulating or restoring the immune system's ability to fight infections and diseases. It can be classified into two types: active and passive. Active immunotherapy boosts the immune system to attack cancer cells, while passive immunotherapy involves the use of immune system components, such as monoclonal antibodies, to target cancer cells.
Immunotherapy encompasses various modalities, including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapy. Monoclonal antibodies are designed to bind to specific targets on cancer cells. Immune checkpoint inhibitors help the immune system recognize and attack cancer cells. Cancer vaccines, like the Sipuleucel-T for prostate cancer, stimulate the immune system to attack specific types of cancer cells. Adoptive cell therapy involves enhancing the natural cancer-fighting ability of the patient's T cells.
Immunotherapy offers several benefits, including precision targeting of cancer cells, reduced side effects, and potential for long-term cancer control. However, it also carries risks, such as immune-related adverse events (irAEs) like inflammation and autoimmune reactions. Physicians should carefully consider these factors when deciding on a treatment plan.
Immunotherapy represents a significant stride in cancer treatment, offering a novel approach that leverages the body's own defenses. As research progresses, it is hoped that this treatment modality will become increasingly effective and widely accessible. Physicians must stay abreast of these developments to provide the best care for their patients.
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
The Growing Role of AI in Cancer Treatment
3.
Tafasitamab Regimen Improves PFS in Relapsed/Refractory Follicular Lymphoma
4.
Lower Prostate Cancer Mortality Linked to Unavailable Clinical Trials.
5.
Powerlifting through breast cancer: How a breast cancer survivor defied chemotherapy with strength training
1.
Drug Exposure in Tumor Microenvironments: Mechanisms, Clinical Implications, and Emerging Strategies
2.
Proteoform Networks in Blood Disorders: Mechanisms, Clinical Implications, and Emerging Therapeutic Strategies
3.
Antibody-Drug Conjugates and the Dawn of Targeted Cancer Therapy in 2025
4.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
5.
Direct Oral Anticoagulants (DOACs) in Atrial Fibrillation: A Comprehensive Review
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
3.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
4.
How Multidisciplinary Teams Support Modern Cancer Care
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation